pharma · Fatty Liver · Inflammatory Disease · GLMD
Galmed Pharmaceuticals
Galmed Pharmaceuticals is a pharma organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker GLMD. Primary therapeutic focus areas include Fatty Liver, Inflammatory Disease, Nonalcoholic Steatohepatitis
16 Ze’ev Tiomkin Street, Tel Aviv, 6578317, IL, USA HQ
2000 Founded
10 Employees
Public company Type
GLMD · NYSE Ticker
Company details
- Status
- Public
- HQ
- 16 Ze’ev Tiomkin Street, Tel Aviv, 6578317, IL, USA
- Founded
- 2000
- Employees
- 10
- Programs
- 13
- Drugs
- 5
- Patents
- 11
A study to compare two different aramchol formulations in healthy volunteers.
Phase 1 · other · Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis
A study to compare two different aramchol formulations in healthy volunteers. for Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis is a Phase 1 program (other) at Galmed Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CGA23001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Galmed Pharmaceuticals
- Phase
- Phase 1
- Modality
- other
- Indication
- Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis
- Status
- active
- Trials
- 1